A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors
NCT00721669
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
DRUG:
IMGN388
Sponsor
ImmunoGen, Inc.